The prognostic value of circulating microRNAs in heart failure: Preliminary results from a genome-wide expression study

Journal of Cardiovascular Medicine

Volumn 16, Issue 6, 2015, Pages 431-437

  Cakmak, Huseyin Altug ^a   Coskunpinar, Ender ^b   Ikitimur, Baris ^b   Barman, Hasan Ali ^b   Karadag, Bilgehan ^b   Tiryakioglu, Necip Ozan ^b   Kahraman, Kadriye ^b   Vural, Vural Ali ^b  

^a Rize Devlet Hastanesi   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

biomarker; circulating; congestive heart failure; microRNA

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; MICRORNA; MICRORNA 122; MICRORNA 1228; MICRORNA 129 3P; MICRORNA 1292; MICRORNA 1296; MICRORNA 155; MICRORNA 182; MICRORNA 1825; MICRORNA 1979; MICRORNA 200A; MICRORNA 21; MICRORNA 299 3P; MICRORNA 30D; MICRORNA 3148; MICRORNA 3155; MICRORNA 3175; MICRORNA 371 3P; MICRORNA 502 5P; MICRORNA 516 5P; MICRORNA 518E; MICRORNA 568; MICRORNA 583; MICRORNA 595; MICRORNA 650; MICRORNA 662; MICRORNA 663B; MICRORNA 744; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN182 MICRORNA, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; PROGNOSTIC ASSESSMENT; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; AGED; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; HEART FAILURE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HEART FAILURE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84929026082     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000233     Document Type: Article

References (32)

1. McMurray J, Komadja M, Anker S, et al. Heart failure: epidemiology, pathophysiology and diagnosis. In: Camm JA, Lü scher TF, Serruys PW, editors. The European Society of Cardiology textbook of cardiovascular medicine. Oxford: Blackwell; 2006. pp. 685-720.
2. Heidenreich PA, Sahay A, Kapoor JR, et al. Divergent trends in survival and readmission following a hospitalization for heart failure in the Veterans Affairs healthcare system 2002 to 2006. JAm Coll Cardiol 2010; 56:362-368.
3. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127:e6-e245.
4. Lai EC. Micro RNAs are complementary to 3'UTR sequence motifs that mediate negative posttranscriptional regulation. Nat Genet 2002; 30:363-364.
5. Bueno MJ, Perez de Castro I, Malumbres M. Control of cell proliferation pathways by microRNAs. Cell Cycle 2008; 7:3143-3148.
6. Li P. MicroRNAs in cardiac apoptosis. J Cardiovasc Trans Res 2010; 3:219-224.
7. Suá rez Y, SessaWC. MicroRNAs as novel regulators of angiogenesis. Circ Res 2009; 104:442-454.
8. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014; 42:D68-D73.
9. Camussi G, Deregibus MC, Bruno S, et al. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010; 78:838-848.
10. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110:483-495.
11. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010; 391:73-77.
12. Chen C, Yang SL, Wang F, et al. Plasma microRNA-361-5p as a biomarker of chronic heart failure. Heart 2010; 96:A189.
13. Tan KS, Armugam A, Sepramaniam S, et al. Expression profile of microRNAs in young stroke patients. PLoS One 2009; 4:e7689.
14. Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106:1035-1039.
15. Fukushima Y, Nakanishi M, Nonogi H, et al. Assessment of plasma miRNAs in congestive heart failure. Circ J 2010; 75:336-340.
16. Hunt SA, Abraham WT, Chin MH, et al., American College of Cardiology Foundation; American Heart Association. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53:e1-e90.
17. Small EM, Frost RJA, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010; 121:1022-1032.
18. Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol 2010; 6:391-398.
19. Sun Y, Zhang K, Fan G, Li J. Identification of circulating microRNAs as biomarkers in cancers: what have we got? Clin Chem Lab Med 2012; 50:2121-2126.
20. Tijsen AJ, Pinto YM, Creemers EE. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012; 303:H1085-H1095.
21. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18:997-1006.
22. De Rosa S, Fichtlscherer S, Lehmann R, et al. Transcoronary concentration gradients of circulating microRNAs. Circulation 2011; 124:1936-1944.
23. Ai J, Zhang R, Li Y, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010; 391:73-77.
24. Ji X, Takahashi R, Hiura Y, et al. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009; 55:1944-1949.
25. Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170:1831-1840.
26. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103:18255-18260.
27. Sayed D, Hong C, Chen IY, et al. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007; 100:416-424.
28. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456:980-984.
29. Villar AV, Garcia R, Merino D, et al. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol 2013; 167:2875-2881.
30. Dong S, Ma W, Hao B, et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol 2014; 7:565-574.
31. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007; 116:258-267.
32. Wei L, Wang M, Qu X, et al. Differential expression of microRNAs during allograft rejection. Am J Transplant 2012; 12:1113-1123.